Redcare Pharmacy stock: MPCM lifts target to 125 euros

Redcare Pharmacy stock traded at 74.60 euros on Lang & Schwarz at 11:31 CET on Tuesday, November 10, 2026, 3.61 percent above the Xetra close of Monday, November 9, at 72.00 euros. The move follows a fresh analyst valuation signal rather than a change to the company's financial outlook.

Borse Express reported that MPCM raised its Redcare Pharmacy price target from 120 euros to 125 euros on November 3 and retained its Buy recommendation. The change lifted the valuation marker by 4.17 percent without altering the stated rating.

Analyst targets remain divided

The higher MPCM target contrasts with Jefferies, which kept both its Buy rating and its 97-euro price target. The difference leaves investors with a wide range of valuation signals, while neither analyst action changes Redcare Pharmacy's operating guidance.

The target increase came after Redcare's third-quarter performance. In its third-quarter release, the company said revenue increased 18 percent year over year to 847 million euros. Prescription revenue rose 31 percent to 358 million euros, while German prescription revenue climbed 56 percent to 197 million euros.

Adjusted EBITDA increased 68 percent to 29 million euros, and the adjusted EBITDA margin expanded to 3.4 percent from 2.4 percent in the prior-year quarter. Redcare also reported a second consecutive quarter with positive net income and free cash flow of 15 million euros.

Prescription growth drives the case

The operating picture remains centered on prescription demand in Germany. Redcare said its active customer base reached 15.2 million at the end of September, while management highlighted stronger profitability in DACH and continued efforts to improve the marketing mix and operating leverage.

For 2026, Redcare maintained its outlook for total revenue growth of 16 percent to 18 percent. The company expects non-prescription revenue growth of 10 percent to 12 percent, German prescription revenue of 730 million to 760 million euros and an adjusted EBITDA margin of 2.5 percent to 3.0 percent.

For investors, the higher MPCM target strengthens the valuation case but does not remove execution risks. Prescription growth, margin expansion and the ability to sustain customer momentum will determine whether the analyst targets are supported by operating results.

The Dutch market backdrop is covered in current AEX market developments.

Further prescription growth, margin progress and the next company update will remain central for investors. More news and analyses on Redcare Pharmacy stock.